Azithromycin induces epidermal differentiation and multivesicular bodies in airway epithelia
Open Access
- 24 June 2019
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 20 (1) , 1-19
Abstract
Azithromycin (Azm) is a macrolide recognized for its disease-modifying effects and reduction in exacerbation of chronic airway diseases. It is not clear whether the beneficial effects of Azm are due to its anti-microbial activity or other pharmacological actions. We have shown that Azm affects the integrity of the bronchial epithelial barrier measured by increased transepithelial electrical resistance. To better understand these effects of Azm on bronchial epithelia we have investigated global changes in gene expression. VA10 bronchial epithelial cells were treated with Azm and cultivated in air-liquid interface conditions for up to 22 days. RNA was isolated at days 4, 10 and 22 and analyzed using high-throughput RNA sequencing. qPCR and immunostaining were used to confirm key findings from bioinformatic analyses. Detailed assessment of cellular changes was done using microscopy, followed by characterization of the lipidomic profiles of the multivesicular bodies present. Bioinformatic analysis revealed that after 10 days of treatment genes encoding effectors of sterol and cholesterol metabolism were prominent. Interestingly, expression of genes associated with epidermal barrier differentiation, KRT1, CRNN, SPINK5 and DSG1, increased significantly at day 22. Together with immunostaining, these results suggest an epidermal differentiation pattern. We also found that Azm induced the formation of multivesicular and lamellar bodies in two different airway epithelial cell lines. Lipidomic analysis revealed that Azm was entrapped in multivesicular bodies linked to different types of lipids, most notably palmitate and stearate. Furthermore, targeted analysis of lipid species showed accumulation of phosphatidylcholines, as well as ceramide derivatives. Taken together, we demonstrate how Azm might confer its barrier enhancing effects, via activation of epidermal characteristics and changes to intracellular lipid dynamics. These effects of Azm could explain the unexpected clinical benefit observed during Azm-treatment of patients with various lung diseases affecting barrier function.Keywords
Funding Information
- Icelandic Centre for Research (142264-0611)
- Icelandic Centre for Research (163757)
This publication has 48 references indexed in Scilit:
- Azithromycin Maintains Airway Epithelial Integrity during Pseudomonas aeruginosa InfectionAmerican Journal of Respiratory Cell and Molecular Biology, 2010
- Azithromycin Treatment Alters Gene Expression in Inflammatory, Lipid Metabolism, and Cell Cycle Pathways in Well-Differentiated Human Airway EpitheliaPLOS ONE, 2009
- Lipids and skin barrier function – a clinical perspectiveContact Dermatitis, 2008
- Differentiation potential of a basal epithelial cell line established from human bronchial explantIn Vitro Cellular & Developmental Biology - Animal, 2007
- Epidermal barrier formation and recovery in skin disordersJournal of Clinical Investigation, 2006
- Novel Effects of Azithromycin on Tight Junction Proteins in Human Airway EpitheliaAntimicrobial Agents and Chemotherapy, 2006
- Surfactant Protein B in Type II Pneumocytes and Intra-Alveolar Surfactant Forms of Human LungsAmerican Journal of Respiratory Cell and Molecular Biology, 2004
- Regulation of lung sufactant protein gene expressionFrontiers in Bioscience-Landmark, 2003
- The electric resistivity of human tissues (100 Hz-10 MHz): a meta-analysis of review studiesPhysiological Measurement, 1999
- Surfactant protein composition of lamellar bodies isolated from rat lungBiochemical Journal, 1991